Differences in Ovarian Reserve Markers and Vitamin D Between Infertile Indian, Arabian and Caucasian Population

NCT ID: NCT02209168

Last Updated: 2018-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2015-11-30

Study Completion Date

2019-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to confirm the difference in ovarian reserve markers and serum vitamine D levels between infertile indian, arabian and caucasian population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

200 caucasian, indian, and arab patients

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Female Infertility Due to Diminished Ovarian Reserve Vitamin D Deficiency Hormone Deficiency Follicular Cyst of Ovary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infertile Indian Population

200 Infertile Indian population

No interventions assigned to this group

Infertile arabian population

200 Infertile Arabian population

No interventions assigned to this group

Infertile caucasian population

200 Infertile Caucasian population

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

WOMEN BETWEEN 21-43 YEARS FIRST OR SECOND IN VITRO FERILIZATION TREATMENT DUE TO TUBAL, MASCULINE OR PREVIOUS INTRAUTERINE INSEMINATION FAIL TREATMENT

Exclusion Criteria

POLYCYSTIC PATIENTS ENDOMETRIOSIS GRADE III OR IV INFLAMMATORY PELVIC DISEASE
Minimum Eligible Age

21 Years

Maximum Eligible Age

43 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

IVI Madrid

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Juan A Garcia-Velasco

Carlos Iglesias, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

CARLOS IGLESIAS, MD

Role: PRINCIPAL_INVESTIGATOR

IVI Madrid

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IVI Madrid

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1405-MAD-020-JG

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lifestyle Factors Study
NCT00989183 COMPLETED
Gender Disparity and Hormones in Cystic Fibrosis
NCT02036879 COMPLETED EARLY_PHASE1